Event

12

September 2019

Isotopes, Global Importance and Opportunities for Canada

7:30am-9:30am | Fairmont Royal York - 100 Front St W, Toronto

To ensure that Canadians benefit from recent advances in nuclear medicine, Canada must build and maintain a domestic supply of both established and emerging medical isotopes, and strengthen its ability to convert raw isotopes into clinical-quality products. This launch event for the CNIC’s inaugural report will detail the Canadian isotope landscape, the current uses and applications of isotopes and demonstrate the economic impact and value of Canadian leadership in isotope production.

James will be joined on stage following the keynote address for a special panel discussion.

- Breakfast will be served -

Member price:
Individual seat: $89 +HST
Table (seats 10): $800 +HST

Regular price:
Individual seat: $110 +HST
Table (seats 10): $990 +HST

Important:
- For information about accessibility, please email morgan@economicclub.ca
- Dietary restriction notes and meal requests must be submitted to morgan@economicclub.ca 72 hrs before the event.
- Refunds/credits: We require three business days notice in advance of the event date for ticket cancellations
*The views expressed on the Economic Club platform are not that of the Economic Club or its affiliates but of the speakers alone and the organizations they represent*

James Scongack

Chair of the Canadian Nuclear Isotope Council
Executive Vice President, Corporate Affairs & Operational Services -- Bruce Power

James Scongack

James Scongack is the Executive-Vice President Corporate Affairs & Operational Services at Bruce Power who generates over 30 percent of Ontario’s electricity. In this role, he is responsible for an organization of 1,000 dedicated people who support the operation of the World’s largest nuclear facility through a range of functions. He is also responsible for business development including the company’s medical isotope ventures.

James served as Vice-President Corporate Affairs and Environment for Bruce Power from 2012-2018 and Head of Corporate Affairs from 2011-2012. From 2006-2011, James served as the Executive Assistant to Bruce Power’s President & CEO.

James was part of the Bruce Power team which successfully negotiated a long-term commercial framework with the Province of Ontario, extending the life of the facility to 2064 enabling the $13 billion life extension program. He also served as executive co-host for the 2015 International Atomic Energy Agency Operational Safety and Review Team Mission.

James sits on the Board of Life Labs, Canada’s largest independent provider of laboratory services.

James is actively involved in many community organizations and charities through the efforts of Bruce Power’s Corporate Social Responsibility Program. He sits on the Board of the Brain Tumor Foundation of Canada and the Development Cabinet for the Pediatric Oncology Group of Ontario.

He has been a long-time supporter of Easter Seals previously serving as a member of the Board and Chair of the Fundraising Committee and received a diamond award of distinction for his efforts in 2016.

He has an Executive MBA from London’s Ivey Business School and a Chartered Director through the DeGroote Business School Directors College. James also holds a Master’s Degree from the University of Guelph College of Management and Economics in Leadership and has completed Master’s-level Project Management certification through York University’s Schulich Business School.

James and his family live in Port Elgin, Ontario where he grew up.

Karin Stephenson

Manager of Commercial Operations
McMaster University

Karin Stephenson

Dr. Karin Stephenson is the Manager of Commercial Operations for McMaster University’s Nuclear Operations and Facilities. Karin has almost 20 years of experience in medical isotopes and radiopharmaceutical development. As the Manager of Commercial Operations, Karin is responsible for maintaining, developing and identifying business opportunities as well as R&D technology/products as it benefits our customers and the growth of the nuclear field. Prior to coming the University, she was the Director of Discovery at the Centre for Probe Development and Commercialization. In that role she was leading the research and discovery of new radiochemistry and molecular imaging agents with medical isotopes for applications in oncology and neurology research.

Karin graduated with her PhD in Chemistry from McMaster University and completed post-doctoral fellowships at the University of Pennsylvania and Centre for Addiction and Mental Health/University of Toronto. She has numerous patents, papers published and has been awarded for her research.

Kathryn Hayashi

President & CEO
Triumf Innovations

Kathryn Hayashi

Kathryn Hayashi is President and CEO of TRIUMF Innovations, the business interface and commercialization arm, connecting TRIUMF, Canada's particle accelerator centre, to the private sector via industry partnerships, licensing, and company creation.

Ms. Hayashi is a Chartered Professional Accountant with more than 25 years of operational and strategic planning, finance and governance experience in not-for-profit organizations, public and private companies, start-ups, and commercialization accelerators/incubators.

Prior to TRIUMF Innovations, she was the Founding Chief Financial Officer of The Centre for Drug Research and Development, Canada’s national drug development and commercialization engine. In addition to her work establishing CDRD as a leader in pre-clinical translational research and commercialization, Ms. Hayashi presides as a Director and Audit Committee Chair of the Center for Commercialization and Cancer Immunotherapy at the Hôpital Maisonneuve-Rosemont, as well as the Discovery Parks technology incubator, and has served on the boards of several spinoff companies.

Susan Marshall

CEO
Brain Tumour Foundation of Canada

Susan Marshall

Susan first became involved with Brain Tumour Foundation of Canada in the early 1990’s when her son Brent was diagnosed with a malignant medulloblastoma. Once Brent was done with treatment, Susan began volunteering on a Brain Tumour Foundation of Canada committee that was dedicated to raising awareness about the disease. Soon after, Susan joined the Board of Directors and later served as president. Susan spent 23 years enjoying growing leadership roles within 3M Canada Company, including Human Resources, Administration, Marketing, Media and Public Relations. The offer to lead Brain Tumour Foundation of Canada as the Executive Director was exciting for Susan and she was thrilled for the opportunity to apply her skills and experience to her passion. In 2002, she made the shift from the corporate to the not-for-profit sector.

Unfortunately, in 2009, Brent was diagnosed with an aggressive anaplastic oliodendroglioma and sadly passed away on May 1, 2010. After taking some time off in 2013, Susan returned in 2015 as the CEO to lead the organization once again. Susan’s involvement with Brain Tumour Foundation of Canada was sparked by her son’s diagnosis, and she has experienced the great loss of her son, but now she feels great joy knowing her work assists the estimated 55,000 Canadians currently living with the disease.

In 2018, Brain Tumour Foundation of Canada became one of the first members of the Canadian Nuclear Isotope Council (CNIC) and Susan is a member of the newly formed Executive Committee. She is proud to be working together with the Council members to raise awareness of the critical role that medical isotopes play in healthcare for Canadians, especially in the treatment of brain tumours.

Tom Burnett

Vice President & General Manager
BWXT Isotope Technologies

Tom Burnett

Thomas R. Burnett is vice president and general manager of BWXT Isotope Technology Group Canada, Inc., (BWXT ITG Canada) a subsidiary of BWX Technologies, Inc. (BWXT).
In his position, Mr. Burnett is responsible for all aspects in the establishment and direction of the BWXT ITG Canada operation. Mr. Burnett joined BWXT in October of 2017.
Prior to joining BWXT, Mr. Burnett held numerous roles in the nuclear medicine industry of varying levels of responsibility in marketing, sales and general management as well as an independent consultant. His experience includes roles with Nordion, Thermo Fisher Scientific, Ernst & Young and Merck Frosst.
Mr. Burnett received a Master of Business Administration from the Ivey School of Business, Western University, London, Ontario. He also holds a Master of Science Degree in organometallic chemistry from Queen’s University, Kingston, Ontario and a Bachelor of Science Degree in chemistry from Western University, London, Ontario.

Travis Besanger

Business & Technical Director - Medical Isotopes
Kinectrics

Travis Besanger

For over a decade Dr. Besanger has built a career in commercialization of radiopharmaceuticals and medical isotope products. Currently, Travis serves as Business & Technical Director - Medical Isotopes at Kinectrics where he Is responsible for building and directing a new commercial medical Isotopes division. In particular Travis Is leading the commercial efforts for Kinectrics to establish large-scale production of Lutetium-177 In partnership with Bruce Power and Framatome.

Before joining Kinectrics Travis held the dual role of Chief Business Officer at the Centre for Probe Development & Commercialization (CPDC) and President of a CPDC subsidiary NuGeneris Specialty Pharmaceuticals. At the CPDC he had accountability for the radiopharmaceutical contract manufacturing (CMO) business unit with responsibility for revenue growth and business strategy. As President of NuGeneris he was responsible for spinning the CMO business out from the CPDC to create a stand-alone company, including securing the required growth and working capital to create an FDA licensed commercial radiotherapy manufacturing facility. Travis also was involved in establishing a Vancouver-based radioisotope company ARTMS that Is focused on the production of Tc-99m and other diagnostic radioisotopes using medical cyclotrons, and he began his career at the Cambridge-based Molecular Insight Pharmaceuticals, a radiopharmaceutical developer that was focused on commercializing targeted radiotherapies for a variety of cancers. Travis received his PhD in Chemistry from McMaster University.

Our Sponsors

porter Interac Canadian Bankers Association pwc
BestLifeRewarded Innovations Boyden
CPA Bespoke Audio Visual Capital One